Predicting Heart Failure Outcomes With Biomarkers and Imaging (NCT07332520) | Clinical Trial Compass
CompletedNot Applicable
Predicting Heart Failure Outcomes With Biomarkers and Imaging
4,000 participantsStarted 2012-01-01
Plain-language summary
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features like epicardial fat density) improves risk prediction compared to using either type of data alone.
This is a retrospective study using existing medical records of patients treated for chronic heart failure at Xinjiang Medical University First Affiliated Hospital between 2012 and 2024. No new patient contact or interventions are involved.
The goal is to enable more accurate, personalized risk assessment across different types of heart failure (HFrEF, HFmrEF, HFpEF).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18 years.
. Confirmed diagnosis of chronic heart failure.
. Treated at the study center between January 1, 2012, and December 31, 2024.
. Availability of both qualifying blood biomarker test results (NT-proBNP and/or high-sensitivity cardiac troponin) and cardiac imaging (echocardiography and/or cardiac CT) performed within a ±3-month window around the index encounter.
Exclusion criteria
. Heart failure primarily due to severe primary valvular disease, acute myocardial infarction, myocarditis, or pulmonary embolism.
. End-stage renal disease requiring dialysis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is already completed and was measuring all-cause mortality — has the data been published yet, and if so, what did the biomarker and imaging findings show about predicting outcomes for someone with my type of heart failure?
2Since this study covered several different types of heart failure — including HFrEF, HFpEF, and HFmrEF — do the results apply specifically to my diagnosis, or were the findings stronger for certain subtypes?
3The trial focused on predicting outcomes rather than testing a new treatment — does that mean the biomarkers or imaging findings from this research could actually change how you monitor or manage my condition going forward?
4Are there specific biomarkers that this study identified as important predictors of mortality that you might now consider testing for in my care?
5Given that this trial is completed, are there any follow-up studies or newer trials building on these findings that might be worth considering as part of my ongoing care?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.